Skip to main content
. 2017 Jun 5;8(40):67218–67226. doi: 10.18632/oncotarget.18365

Figure 4. AMPKα dominant negative mutation abolishes hernandezine-induced anti-LPS response.

Figure 4

U937 cells were constructed with the dominant negative mutant AMPKα (T172A, “dnAMPKα”), the constitutively activate AMPKα (T172D, “caAMPKα”) or the empty vector (pSuper-puro, “Vec”), and stable cells were established; Cells were treated with hernandezine (30 μM) or plus LPS (100 ng/mL) for indicated time, expression of listed proteins was tested by Western blotting assay (A); TNFα mRNA expression (B and D) and protein content (in conditional medium, (C and E) were tested by qRT-PCR assay and ELISA assay, respectively. *p<0.05 vs. LPS only group. # p<0.05 vs. hernandezine of “Vec” group. Experiments in this figure were repeated three times, and similar results were obtained.